phospho-CBL2 (Tyr731)抗体特异性结合抗原：抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而，抗体可通过与病毒或**的特异性结合，直接发挥中和病毒的作用。
产品编号xy- 3089R
英文名称phospho-CBL2 (Tyr731)
中文名称磷酸化原癌蛋白CBL2抗体
别 名phospho-C CBL (Tyr731); CBL2 (phospho-Tyr731); CBL2 (phospho-Tyr731); p-CBL2 (Tyr731); p-CBL2 (Y731); C CBL; Cas-Br-M (murine) ecotropic retroviral transforming sequence; Casitas B lineage lymphoma proto oncogene; CBL 2;E3 ubiquitin protein ligase CBL; Oncogene CBL2; Proto oncogene c CBL; RGD1561386; RING finger protein 55; RNF55v Signal transduction protein CBL; 4732447J05Rik; CBL_HUMAN.
说 明 书100ul
产品类型磷酸化抗体
研究领域肿瘤 细胞生物 **学 信号转导
抗体来源Rabbit
克隆类型Polyclonal
phospho-CBL2 (Tyr731)抗体交叉反应 Human, Mouse, Rat, Dog, Pig, Cow,
产品应用ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量100kDa
细胞定位细胞浆
性 状Lyophilized or Liquid
浓 度1mg/ml
免 疫 原KLH conjugated Synthesised phosphopeptide derived from human CBL2 around the phosphorylation site of Tyr731:CT(p-Y)EA
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
phospho-CBL2 (Tyr731)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产品介绍background:
The proto oncogene c CBL was initially identified as the cellular homologue of v CBL oncogene that induces pre B cell lymphomas and myeloid leukemias in mice. In more recent studies CBL has been shown to be a negative regulator of tyrosine kinase signaling. The ubiquitin ligase activity of CBL leads to the degradation of tyrosine kinases, thus attenuating the signal of receptors. Targets of CBL include activated protein tyrosine kinases belonging to the Src and Syk/Zap 70 families. An additional mechanism to attenuate receptor signaling is thought to be achieved by CBL’s interaction with downstream targets of tyrosine kinases, such as PI 3K and Vav.
Function:
Adapter protein that functions as a negative regulator of many signaling pathways that are triggered by activation of cell surface receptors. Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Recognizes activated receptor tyrosine kinases, including KIT, FLT1, FGFR1, FGFR2, PDGFRA, PDGFRB, EGFR, CSF1R, EPHA8 and KDR and terminates signaling. Recognizes membrane-bound HCK and other kinases of the SRC family and mediates their ubiquitination and degradation. Participates in signal transduction in hematopoietic cells. Plays an important role in the regulation of osteoblast differentiation and apoptosis. Essential for osteoclastic bone resorption. The Tyr-731 phosphorylated form induces the activation and recruitment of phosphatidylinositol 3-kinase to the cell membrane in a signaling pathway that is critical for osteoclast function.
Subunit:
Interacts (phosphorylated at Tyr-731) with PIK3R1. Associates with NCK via its SH3 domain. The phosphorylated C-terminus interacts with CD2AP via its second SH3 domain. Binds to UBE2L3. Interacts with adapters SLA, SLA2 and with the phosphorylated C-terminus of SH2B2. Interacts with EGFR, SYK and ZAP70 via the highly conserved Cbl-N region. Also interacts with SORBS1 and INPPL1/SHIP2. Interacts with phosphorylated LAT2. May interact with CBLB (By similarity). Interacts with ALK, AXL, BLK, FGR and FGFR2. Interacts with CSF1R, EPHB1, FLT1, KDR, PDGFRA and PDGFRB; regulates receptor degradation through ubiquitination. Interacts with HCK and LYN. Interacts with TEK/TIE2 (tyrosine phosphorylated).
Subcellular Location:
Cytoplasm. Cell membrane. Note=Colocalizes with FGFR2 in lipid rafts at the cell membrane.
Post-translational modifications:
Phosphorylated on tyrosine residues by ALK, EGFR, SYK, FYN and ZAP70 (By similarity). Phosphorylated on tyrosine residues in response to FLT1 and KIT signaling. Phosphorylated on tyrosine residues by INSR and FGR. Phosphorylated on several tyrosine residues by constitutively activated FGFR3. Not phosphorylated at Tyr-731 by FGFR3. Phosphorylated on tyrosine residues by activated CSF1R, PDGFRA and PDGFRB. Phosphorylated on tyrosine residues by HCK.
Ubiquitinated, leading to its degradation via the proteasome.
DISEASE:
Noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia (NSLL) [MIM:613563]: A syndrome characterized by a phenotype reminiscent of Noonan syndrome. Clinical features are highly variable, including facial dysmorphism, short neck, developmental delay, hyperextensible joints and thorax abnormalities with widely spaced nipples. The facial features consist of triangular face with hypertelorism, large low-set ears, ptosis, and flat nasal bridge. Some patients manifest cardiac defects. Some have an increased risk for certain malignancies, particularly juvenile myelomonocytic leukemia. Note=The disease is caused by mutations affecting the gene represented in this entry.
Similarity:
Contains 1 Cbl-PTB (Cbl-type phosphotyrosine-binding) domain.
Contains 1 RING-type zinc finger.
Contains 1 UBA domain.
Gene ID:
867
phospho-CBL2 (Tyr731)抗体（antibody,
Ab）是由效应B细胞（效应**B细胞）分泌，机体用于抵御外来物质，如病毒，**等抗原，结构呈“Y”字型的球状蛋白质，仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质，均被称作抗原，因此对于抗抗体（能够结合抗体的抗体）来说，抗体本身也是一种抗原物质。
phospho-CBL2 (Tyr731)抗体普通抗体重链和轻链的结构
重链结构：普通的**球蛋白具有2条重链（H链），分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型，对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构： 普通**球蛋白具有2条轻链（L链），分子质量约25kDa，有κ链和λ链两种亚型，这两种轻链决定了Ig的亚型类别（IgG1，IgG2，IgG3，IgG4）。一个天然的Ig分子两条轻链总是相同的，但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同，正常人血清**球蛋白κ链：λ链约为2：1，而在小鼠的比例为20：1。
2.2抗体Fab段和Fc段
IgG经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应；经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段（fragment of antigen binding，Fab），相当于抗体分子的两个臂，由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段（fragment crystallizable，Fc）相当于Ig的CH2和CH3结构域，是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区，以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域，相当于Y字结构下面那一部分。
合格 SLC38A9 溶质载体家族蛋白38成员A8抗体
合格 SLC39A14 溶质载体家族蛋白39成员A14抗体
合格 SLC39A2 溶质载体家族蛋白39成员A2抗体
合格 合格 SLC39A4 溶质载体家族蛋白39成员A4抗体
合格 SLC39A5 溶质载体家族蛋白39成员A5抗体
合格 SLC22A1 溶质载体家族蛋白22成员A1/有机阳离子转运蛋白1抗体
合格 RGS13 G蛋白信号转导调节因子13抗体
合格 RGS17 G蛋白信号转导调节因子17抗体
合格 RGS18 G蛋白信号转导调节因子18抗体
合格 RGS3 G蛋白信号转导调节因子3抗体
合格 RGS6 G蛋白信号转导调节因子6抗体
合格 RHBG RH家族B型糖蛋白RHBG抗体
合格 MCP-3 单核细胞趋化蛋白3抗体
合格 合格 Rho guanine exchange factor 16 鸟嘌呤交换因子16抗体
合格 RhoF RhoF蛋白抗体
合格 phospho-Parkin (Ser131) 磷酸化帕金森病蛋白2抗体
合格 PARN 多聚腺苷酸特异性核糖核酸抗体
合格 PARP14 多腺苷二磷酸多聚酶PARP14抗体
合格 PARP8 多腺苷二磷酸多聚酶PARP8抗体
合格 PARVB 小细胞蛋白PARVβ抗体
合格 PARVA 基质重塑相关蛋白PARVA抗体
合格 phospho-Src (Ser75) 磷酸化src原癌基因抗体
合格 phospho-Parvin alpha (Ser8) 磷酸化基质重塑相关蛋白PARVA抗体
合格 PASD1/CT63 癌/睾丸抗原63
合格 合格 PATL2 PATL2蛋白抗体
合格 ARP1B/PC3 肌动蛋白相关蛋白1B抗体
合格 PCBD1 蝶呤甲醇胺脱水酶1抗体
合格 PCBD2 蝶呤甲醇胺脱水酶2抗体
合格 PCBP1 异构核糖核蛋白E1抗体
合格 PCBP2 异构核糖核蛋白E2抗体
合格 PCCA 丙酰辅酶A羧化酶α链抗体
合格 MITF MITF相关转录因子抗体
合格 PCCB 丙酰辅酶A羧化酶β链抗体
合格 PCTAIRE1 周期素依赖性激酶PCTAIRE1抗体
合格 phospho-SMAD5 (Ser463 + Ser465) 磷酸化细胞信号转导分子SMAD5抗体
合格 phospho-SMC1 (Ser966) 磷酸化染色体结构维持蛋白质１抗体